Windtree Therapeutics, Inc. - Common Stock (WINT)
Frequently Asked Questions About Windtree Therapeutics, Inc. - Common Stock (WINT)
How does Windtree plan to fund its operations?
Windtree Therapeutics plans to fund its operations through a combination of public equity offerings, partnerships, grants, and collaborations with larger pharmaceutical firms. By diversifying its funding sources, the company aims to ensure adequate capital for its research and development activities.
How does Windtree Therapeutics approach partnerships?
Windtree Therapeutics actively seeks partnerships with other biotechnology and pharmaceutical companies, as well as research institutions, to enhance its development capabilities and accelerate the clinical development of its assets. These collaborations can provide valuable resources, expertise, and access to broader markets.
How has Windtree adapted to market challenges?
Windtree has demonstrated adaptability to market challenges by focusing on agile development strategies, embracing innovation in drug formulations, and seeking collaborations that enhance its research capabilities. The company continues to assess market trends and unmet needs to position its therapies effectively.
Is Windtree Therapeutics publicly traded?
Yes, Windtree Therapeutics, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol 'WINT'. The company has made its shares available to investors to raise capital for its research and development activities.
What are the recent milestones or achievements of Windtree?
Recent milestones for Windtree Therapeutics have included successful completion of clinical trial phases for AEROSURF and securing funding to support ongoing research and development. These achievements underscore the company’s commitment to bringing novel therapies to market and improving patient care in the critical care setting.
What are Windtree's lead product candidates?
Windtree's lead product candidates include AEROSURF, an investigational drug designed for the treatment of respiratory distress syndrome in premature infants, and other therapies aimed at adult patients suffering from acute respiratory conditions. These products are in various stages of development and clinical trials.
What does Windtree Therapeutics, Inc. do?
Windtree Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for critical care patients, including those suffering from respiratory disorders. The company specializes in the development of treatments that can improve lung function and facilitate breathing, particularly in patients with acute conditions, such as pulmonary diseases.
What is AEROSURF?
AEROSURF is an investigational drug product developed by Windtree Therapeutics, designed for the treatment of surfactant deficiency in premature infants at risk for or suffering from neonatal respiratory distress syndrome. It combines a surfactant with an aerosol delivery system to improve lung function.
What is the mission of Windtree Therapeutics?
The mission of Windtree Therapeutics is to develop life-saving therapies for patients with critical medical conditions, particularly in the area of respiratory care. They strive to address significant unmet needs by leveraging innovative drug delivery technologies and therapeutic approaches.
What is the primary focus of Windtree's research?
Windtree's primary research focus is on developing products that address unmet medical needs in critical care and respiratory medicine. They aim to create therapies that can significantly improve patient outcomes in conditions such as acute respiratory distress syndrome (ARDS) and other related respiratory issues.
What is the significance of pulmonary surfactant in respiratory treatment?
Pulmonary surfactant is a substance that reduces surface tension in the lungs, facilitating proper lung expansion and gas exchange. In conditions like neonatal respiratory distress syndrome, surfactant replacement therapy is crucial for improving lung function and reducing mortality rates among affected infants.
What is Windtree's pipeline strategy?
Windtree's pipeline strategy involves developing a range of innovative therapeutic candidates through a combination of internal development and strategic partnerships. The company aims to advance its lead products, like AEROSURF, while also exploring new opportunities to expand its portfolio in respiratory and critical care therapeutics.
What is Windtree's vision for the future?
Windtree Therapeutics envisions a future where its therapies significantly improve patient outcomes in critical care and respiratory medicine. By focusing on innovative solutions and advancing its development pipeline, the company aims to become a leader in its field, making a meaningful impact on the lives of patients.
What regulatory processes does Windtree undergo?
Like all biotechnology companies, Windtree Therapeutics must navigate a rigorous regulatory process to obtain approval for its product candidates. This includes conducting clinical trials to gather safety and efficacy data, as well as submitting New Drug Applications (NDAs) to the Food and Drug Administration (FDA) and other regulatory bodies around the world.
What role do investors play in Windtree's growth?
Investors play a critical role in Windtree Therapeutics' growth by providing the necessary capital to advance its clinical programs and operations. Their support allows the company to pursue innovations, conduct essential research, and bring new therapies to market, ultimately benefiting both patients and shareholders.
What stage of development is AEROSURF currently in?
As of October 2023, AEROSURF is in the late stages of clinical development, having undergone multiple clinical trials to assess its effectiveness and safety in preterm infants. The results from these trials are critical in determining its path towards regulatory approval.
What therapeutic areas does Windtree target?
Windtree Therapeutics primarily targets therapeutic areas related to critical care medicine, with a strong focus on respiratory therapies. This includes conditions like neonatal respiratory distress syndrome, acute respiratory distress syndrome (ARDS), and other serious pulmonary conditions.
Where is Windtree Therapeutics headquartered?
Windtree Therapeutics is headquartered in Warrington, Pennsylvania, which places it in proximity to major research institutions and healthcare facilities that are pivotal for collaborations and clinical trials.
Who founded Windtree Therapeutics?
Windtree Therapeutics, Inc. originated from earlier entities focused on developing respiratory therapies and has evolved through various stages and leadership. While the company has had different leaders over time, its current strategic direction is spearheaded by a team that integrates expertise in biopharmaceutical development.
What is the current price of Windtree Therapeutics, Inc. - Common Stock?
The current price of Windtree Therapeutics, Inc. - Common Stock is 1.300
When was Windtree Therapeutics, Inc. - Common Stock last traded?
The last trade of Windtree Therapeutics, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Windtree Therapeutics, Inc. - Common Stock?
The market capitalization of Windtree Therapeutics, Inc. - Common Stock is 6.69M
How many shares of Windtree Therapeutics, Inc. - Common Stock are outstanding?
Windtree Therapeutics, Inc. - Common Stock has 5.15M shares outstanding.